Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recruiting × HR+/HER2- Breast Cancer × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 142 Neoplasms 104 Colorectal Neoplasms 85 Breast Neoplasms 83 Pancreatic Neoplasms 74 Leukemia, Myeloid, Acute 73 Melanoma 70 Recurrence 68 Neoplasm Metastasis 68 Prostatic Neoplasms 65 Multiple Myeloma 65 Ovarian Neoplasms 64 Stomach Neoplasms 56 Squamous Cell Carcinoma of Head and Neck 51 Lung Neoplasms 48 Lymphoma 46 Triple Negative Breast Neoplasms 43 Advanced Solid Tumor 43 Precursor Cell Lymphoblastic Leukemia-Lymphoma 42 Lymphoma, Non-Hodgkin 41 Glioblastoma 41 Endometrial Neoplasms 41 Carcinoma, Renal Cell 34 Carcinoma, Hepatocellular 34 Uterine Cervical Neoplasms 33 Advanced Solid Tumors 29 Brain Neoplasms 28 Small Cell Lung Carcinoma 27 Sarcoma 27 Lymphoma, Large B-Cell, Diffuse 27

Interventions

Letrozole 1 Fulvestrant 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06998407 2026-02-20

AVZO-023-1001

Avenzo Therapeutics, Inc.

Phase 1/2 Recruiting

HR+/HER2- Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡